On Friday, Shares of General Electric Company (NYSE:GE), gained 0.12% to $24.49.
The GE Foundation is announcing its commitment to global safe surgery with the launch of the Safe Surgery 2020 Initiative. With just under a third of all deaths (16.9 million in 2010) from conditions treatable with surgery, the global need for a solution is critical. Safe Surgery 2020 aims to reduce maternal and trauma-related mortality and create stronger health systems by transforming access, quality and safety of surgical care in regions that need it most: low-and middle-income countries. The official launch of the initiative is taking place at a panel negotiation on surgery in the developing world as a UN General Assembly (UNGA) satellite event on Friday, September 25 at 30 Rockefeller Plaza.
With a commitment of $25 million over the next three years, the Initiative will seek to accelerate access to safe surgery and anesthesia worldwide through investments in three core pillars: leadership development and facility toolkit; innovation; and elevating ideas.
GE Foundation is partnering with several organizations on Safe Surgery 2020 to:
- Provide leadership development on-the-ground in low- and middle-income countries to improve the quality of surgical care in target facilities
- Identify, test and scale innovations, accelerating progress in safe surgery both at the facility-level and more broadly
- Identify proven programs to improve surgical care, and elevate the profile of surgery on a global stage
General Electric Company (GE) is a diversified infrastructure and financial services company. The products and services of the Company range from aircraft engines, power generation, oil and gas production equipment, and household appliances to medical imaging, business and consumer financing and industrial products.
Shares of Merck & Co., Inc. (NYSE:MRK), declined -1.92% to $49.62, during its last trading session.
Merck & Co., known as MSD outside the United States and Canada, recently declared new findings from the KEYNOTE-028 Phase 1b study, the clinical trial investigating the use of the company’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in multiple, difficult-to-treat cancers. Data from this trial, to be presented at the European Cancer Congress (ECC) in Vienna, Austria, Sept. 25-29, comprise the first-time findings for KEYTRUDA in two gastrointestinal cancers, advanced anal cancer and advanced biliary tract cancer, and add to Merck’s growing body of clinical data for KEYTRUDA.
KEYNOTE-028 is an ongoing multi-cohort, non-randomized Phase 1b basket trial – a trial design that allows for the study of multiple sub-populations of different tumor or histological types within one study. The study is evaluating the safety, tolerability, and anti-tumor activity of KEYTRUDA monotherapy (10 mg/kg dosed every two weeks) in more than 450 patients across 20 different types of cancer. The study was designed to evaluate patients with advanced solid tumors that express PD-L1 and which have not responded to current therapy or for which current therapy is not appropriate.
The KEYTRUDA clinical development program has rapidly expanded to encompass more than 30 tumor types in more than 130 clinical trials, of which more than 70 trials combine KEYTRUDA with other cancer treatments. Registration-enabling trials of KEYTRUDA monotherapy are presently enrolling patients in melanoma, non-small cell lung cancer (NSCLC), head and neck cancer, bladder cancer, gastric cancer, colorectal cancer, and Hodgkin Lymphoma, with further trials in planning for other cancers.
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures.
Shares of Bristol-Myers Squibb Co (NYSE:BMY), declined -2.51% to $60.25, during its last trading session.
Bristol-Myers Squibb Company - Actor Jack Huston, a star of the hit television show Boardwalk Empire and the forthcoming remake of Ben Hur, took on an important new role as lung cancer advocate as he challenged Europeans to A.C.T. – be Aware, get Checked, and Talk with their doctor about lung cancer. After losing his grandfather to lung disease and his best friend and mentor, Peter Blythe, to lung cancer, Huston was motivated to take action by partnering with Bristol-Myers Squibb Company (BMY) and leading advocacy group Lung Cancer Europe (LuCE) to ask the public, particularly those at high risk, what’s their Next Lung Cancer A.C.T.?
Lung cancer is the number one cancer killer in Europe with an estimated 353,000 deaths each year – more than breast cancer, colorectal and prostate cancers combined. In Europe, lung cancer is the third most common cancer among women. Despite the growing prevalence, a new survey conducted among more than 8,200 participants in nine European countries showed that lung cancer knowledge is very low, with nearly six in 10 people (57%) surveyed saying that they are not knowledgeable about the disease. Further, one in five people (20%) could not identify the symptoms of lung cancer, counting persistent cough, and one in 10 people (10%) do not know the risk factors, such as exposure to cigarette smoking.
Huston, together with lung cancer advocates and oncologists, unveiled the survey results at the European Cancer Congress (ECC) 2015 in Vienna, as well as a short film highlighting the personal stories of lung cancer patients.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession.
Finally, J C Penney Company Inc (NYSE:JCP), ended its last trade with 1.07% gain, and closed at $9.43.
J C. Penney Company, declared that John Tighe has been promoted to executive vice president, chief merchant effective Oct. 1, reporting to the Company`s Chief Executive Officer Marvin Ellison. Tighe most recently served as senior vice president and senior general merchandise manager for the men`s, children`s, footwear, handbag and intimate apparel divisions. He will succeed Elizabeth “Liz” Sweney who will serve in an advisory role through the end of the fiscal year, at which time she will retire from the Company after 16 years of service.
Tighe began his 24-year retail career at May Department Stores in a series of merchandising roles that spanned more than a decade at Filene`s and Meier & Frank. JCPenney recruited Tighe as a buyer in 2002, and he was later promoted to divisional vice president, overseeing various apparel categories such as junior`s sportswear, missy casual and special sizes before leading jcp.com in 2009 as senior vice president. In 2010, he was designated senior vice president and general merchandise manager of the Company`s home division before transitioning to men`s in 2012.
J C. Penney Company, Inc. (JCPenney) is a holding company. The Company’s operating partner is J. C. Penney Corporation, Inc. (JCP). The Company’s business comprises of selling merchandise and services to consumers through its department stores and Website at jcpenney.com, which utilizes applications for desktop, mobile and tablet devices.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
